UAE Ministry of Health and Prevention Approves Biomerica's Fortel Kidney Disease Test For Sale

• Regulatory milestone enables commercial expansion into high-need international market
• 10-minute test detects early signs of kidney damage using a simple urine sample
• Addresses global public health burden of Chronic Kidney Disease (CKD), with high relevance in the UAE
  
   

IRVINE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, announced that its Fortel® Kidney Disease (Microalbumin) Test has been approved for sale by the United Arab Emirates (UAE) Ministry of Health and Prevention. This key regulatory milestone enables Biomerica to offer its innovative test across the UAE, a region facing a high burden of chronic kidney disease (CKD).

The Fortel® Kidney Disease Test is a rapid, easy-to-use diagnostic tool that provides accurate results in 10 minutes using a urine sample. By detecting low levels of microalbumin in urine (a critical early marker), the test can enable the early detection of kidney disease. Individuals with diabetes, hypertension, obesity and those over the age of 65 are at significantly increased risk for developing chronic kidney disease (CKD) and should be tested frequently. CKD is a worldwide public health problem that is highly underrecognized and more than 80% of at-risk patients are not diagnosed. Kidney disease enhances the risk of major non-communicable diseases including ischemic heart disease, stroke, cancer, etc. By 2040, CKD is projected to be the 5th highest cause of years of life lost globally.

Early detection of CKD allows for timely intervention that can slow or prevent progression to end-stage renal disease, requiring dialysis or kidney transplantation. In addition to reducing morbidity and mortality, early diagnosis can also lower the substantial economic burden associated with disease progression.